Emyria Limited | Data-backed drug development and clinical care

We Are

A clinical-stage biotech informed by patient experience. Tackling unmet needs in neuroscience and mental health.

Drug Development

ULTRA - PURE CBD MEDICINES

Powered By Real World Evidence

Novel Formulation	Medical Indication	Dose Optimisation	Safety Trials	Pivotal Trials	Approval
EMD-RX5 Over the Counter	Psychological Distress
EMD-RX5 Over the Counter	Irritable Bowel Syndrome
EMD-RX7 Prescription	Multiple Medical Conditions
OTHERS IN DEVELOPMENT Prescription	Multiple Medical Conditions

New Drug Discovery

MDMA - INSPIRED MEDICINES

Ongoing Library Expansion

Program	Medical Indication	Discovery	Pre-Clinical	Phase 1	Pivotal Trials	Approval
Program 01 HIGHER POTENCY MDMA	e.g. Drug-assisted psychotherapy
Program 02 SELECTED BRAIN TARGETS	e.g. Parkinson's
Program 03 SELECTED NON-BRAIN TARGETS	e.g. Fibrotic Disease

Innovation

Technology	Description	Concept	Design	Submission	Approval	Launch
OPENLY REMOTE HEALTH TRACKER	Vital Signs Tracked Via Smartphone Camera	CLASS 2A MEDICAL DEVICE

News & Events

Get up to speed with our latest news.

0

%

FDA approvals where real-world evidence (RWE) was provided, and growing.

0

+

Unique data points collected per patient.

$

0

T USD

Trillion USD cost of chronic disease and mental health per year in the US.

For Investors

Ours is a collaborative vision and venture. We’re bringing people and partners together for the greater good: patients, clinicians, researchers, medical innovators and, of course, investors.